Granted Patent
B2
US 12,544,448 · App. 18/651,408 · Granted Feb 10, 2026
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
Inventors:
James Bradley Aggen (Redwood City, CA); G. Leslie Burnett (Redwood City, CA); Jennifer Pitzen (Redwood City, CA); Arun P. Thottumkara (Redwood City, CA)
Assignee:
REVOLUTION MEDICINES, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
Claims (5)
1 . A compound having the formula
2 . A compound having the formula
3 . A compound having the formula
4 . A compound having the formula
5 . A compound having the formula
Assignments (2)
SECURITY INTEREST
Recorded Jun 25, 2025
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 071721/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 5, 2025
From: PITZEN, JENNIFER; GLIEDT, MICAH JAMES EVANS; BURNETT, G. LESLIE; AGGEN, JAMES BRADLEY; KISS, GERT; CREGG, JAMES JOSEPH; SEMKO, CHRISTOPHER MICHAEL; WON, WALTER; WANG, GANG; LEE, JULIE CHU-LI; THOTTUMKARA, ARUN P.; GILL, ADRIAN LIAM; MELLEM, KEVIN T.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 070121/0612 →
Continuity (7)
Provisional Application
62665435
· May 1, 2018
Provisional Application
62752874
· Oct 30, 2018
Provisional Application
62836036
· Apr 18, 2019
References Cited (344)
US 3929992A
· Sehgal et al.
· 1975
[cited by applicant]
US 4316885A
· Rakhit
· 1982
[cited by applicant]
US 4650803A
· Stella et al.
· 1987
[cited by applicant]
US 4861760A
· Mazuel et al.
· 1989
[cited by applicant]
US 4911920A
· Jani et al.
· 1990
[cited by applicant]
US 5023263A
· Von Burg
· 1991
[cited by applicant]
US 5023264A
· Caufield et al.
· 1991
[cited by applicant]
US 5100883A
· Schiehser
· 1992
[cited by applicant]
US 5102876A
· Caufield
· 1992
[cited by applicant]
US 5118677A
· Caufield
· 1992
[cited by applicant]
US 5118678A
· Kao et al.
· 1992
[cited by applicant]
US 5120726A
· Failli et al.
· 1992
[cited by applicant]
US 5120842A
· Failli et al.
· 1992
[cited by applicant]
US 5130307A
· Failli et al.
· 1992
[cited by applicant]
US 5151413A
· Caufield et al.
· 1992
[cited by applicant]
US 5162333A
· Failli et al.
· 1992
[cited by applicant]
US 5177203A
· Failli et al.
· 1993
[cited by applicant]
US 5212162A
· Missel et al.
· 1993
[cited by applicant]
US 5221670A
· Caufield
· 1993
[cited by applicant]
US 5233036A
· Hughes
· 1993
[cited by applicant]
US 5252579A
· Skotnicki et al.
· 1993
[cited by applicant]
US 5256790A
· Nelson
· 1993
[cited by applicant]
US 5258389A
· Goulet et al.
· 1993
[cited by applicant]
US 5260300A
· Hu
· 1993
[cited by applicant]
US 5262423A
· Kao
· 1993
[cited by applicant]
US 5262564A
· Kun et al.
· 1993
[cited by applicant]
US 5302584A
· Kao et al.
· 1994
[cited by applicant]
US 5344833A
· Hughes
· 1994
[cited by applicant]
US 5362718A
· Skotnicki et al.
· 1994
[cited by applicant]
US 5373014A
· Failli et al.
· 1994
[cited by applicant]
US 5378836A
· Kao et al.
· 1995
[cited by applicant]
US 5385908A
· Nelson et al.
· 1995
[cited by applicant]
US 5385909A
· Nelson et al.
· 1995
[cited by applicant]
US 5385910A
· Ocain et al.
· 1995
[cited by applicant]
US 5389639A
· Failli et al.
· 1995
[cited by applicant]
US 5391730A
· Skotnicki et al.
· 1995
[cited by applicant]
US 5403841A
· Lang et al.
· 1995
[cited by applicant]
US 5411967A
· Kao et al.
· 1995
[cited by applicant]
US 5434260A
· Skotnicki et al.
· 1995
[cited by applicant]
US 5463048A
· Skotnicki et al.
· 1995
[cited by applicant]
US 5480988A
· Failli et al.
· 1996
[cited by applicant]
US 5480989A
· Kao et al.
· 1996
[cited by applicant]
US 5489680A
· Failli et al.
· 1996
[cited by applicant]
US 5491231A
· Nelson et al.
· 1996
[cited by applicant]
US 5504091A
· Molnar-Kimber et al.
· 1996
[cited by applicant]
US 5527907A
· Or et al.
· 1996
[cited by applicant]
US 5563145A
· Failli et al.
· 1996
[cited by applicant]
US 5583139A
· Or et al.
· 1996
[cited by applicant]
US 5665772A
· Cottens et al.
· 1997
[cited by applicant]
US 5741677A
· Kozlowski et al.
· 1998
[cited by applicant]
US 5780462A
· Lee et al.
· 1998
[cited by applicant]
US 5985890A
· Cottens et al.
· 1999
[cited by applicant]
US 6200985B1
· Cottens et al.
· 2001
[cited by applicant]
US 6277983B1
· Shaw et al.
· 2001
[cited by applicant]
US 6323201B1
· Carson et al.
· 2001
[cited by applicant]
US 6342507B1
· Naicker et al.
· 2002
[cited by applicant]
US 6358969B1
· Shelley et al.
· 2002
[cited by applicant]
US 6562819B2
· Carson et al.
· 2003
[cited by applicant]
US 6720344B2
· Kerwin et al.
· 2004
[cited by applicant]
US 7074804B2
· Zhu et al.
· 2006
[cited by applicant]
US 7160867B2
· Abel et al.
· 2007
[cited by applicant]
US 7241771B2
· Zhu
· 2007
[cited by applicant]
US 7429596B2
· Tanaka et al.
· 2008
[cited by applicant]
US 7585868B2
· Knight et al.
· 2009
[cited by applicant]
US 8101602B2
· Menear et al.
· 2012
[cited by applicant]
US 8410131B2
· Lane et al.
· 2013
[cited by applicant]
US 8492405B2
· Yasuma et al.
· 2013
[cited by applicant]
US 8604032B2
· Ren et al.
· 2013
[cited by applicant]
US 8642604B2
· Knight et al.
· 2014
[cited by applicant]
US 8697709B2
· Dar et al.
· 2014
[cited by applicant]
US 8785454B2
· Ren et al.
· 2014
[cited by applicant]
US 8980899B2
· Korennykh et al.
· 2015
[cited by applicant]
US 9321772B2
· Dar et al.
· 2016
[cited by applicant]
US 9358229B2
· Vannucchi et al.
· 2016
[cited by applicant]
US 9493467B2
· Knight et al.
· 2016
[cited by applicant]
US 9512125B2
· Shokat et al.
· 2016
[cited by applicant]
US 9603891B2
· Bae et al.
· 2017
[cited by applicant]
US 9629843B2
· Shokat et al.
· 2017
[cited by applicant]
US 20040235762A1
· Abel et al.
· 2004
[cited by applicant]
US 20050085472A1
· Tanaka et al.
· 2005
[cited by applicant]
US 20050101624A1
· Betts et al.
· 2005
[cited by applicant]
US 20050192311A1
· Isozaki et al.
· 2005
[cited by applicant]
US 20080249123A1
· Gu et al.
· 2008
[cited by applicant]
US 20090074831A1
· Falotico et al.
· 2009
[cited by applicant]
US 20090124638A1
· Shokat et al.
· 2009
[cited by applicant]
US 20090131631A1
· Krafft et al.
· 2009
[cited by applicant]
US 20090181988A1
· Tanaka et al.
· 2009
[cited by applicant]
US 20090253733A1
· Rhodes et al.
· 2009
[cited by applicant]
US 20090270426A1
· Knight et al.
· 2009
[cited by applicant]
US 20090274739A1
· Marks et al.
· 2009
[cited by applicant]
US 20090292118A1
· Lee et al.
· 2009
[cited by applicant]
US 20090312319A1
· Ren et al.
· 2009
[cited by applicant]
US 20100009963A1
· Knight et al.
· 2010
[cited by applicant]
US 20100190749A1
· Ren et al.
· 2010
[cited by applicant]
US 20100190980A1
· Umemiya et al.
· 2010
[cited by applicant]
US 20110046165A1
· Ren et al.
· 2011
[cited by applicant]
US 20110098241A1
· Sun et al.
· 2011
[cited by applicant]
US 20110124641A1
· Ren et al.
· 2011
[cited by applicant]
US 20110144134A1
· Shokat et al.
· 2011
[cited by applicant]
US 20110172228A1
· Ren et al.
· 2011
[cited by applicant]
US 20110224223A1
· Shokat et al.
· 2011
[cited by applicant]
US 20110269779A1
· Wilson et al.
· 2011
[cited by applicant]
US 20110281866A1
· Ren et al.
· 2011
[cited by applicant]
US 20110301144A1
· Knight et al.
· 2011
[cited by applicant]
US 20120065154A1
· Tanaka et al.
· 2012
[cited by applicant]
US 20120065426A1
· Watanabe et al.
· 2012
[cited by applicant]
US 20120294930A1
· Ren et al.
· 2012
[cited by applicant]
US 20120322814A1
· Korennykh et al.
· 2012
[cited by applicant]
US 20120329776A1
· Ren et al.
· 2012
[cited by applicant]
US 20130289271A1
· Perrin-Ninkovic et al.
· 2013
[cited by applicant]
US 20140066462A1
· Pearce et al.
· 2014
[cited by applicant]
US 20140288096A1
· Knight et al.
· 2014
[cited by applicant]
US 20150031881A1
· Tanaka et al.
· 2015
[cited by applicant]
US 20150368297A1
· Bae et al.
· 2015
[cited by applicant]
US 20160000789A1
· Shokat et al.
· 2016
[cited by applicant]
US 20160168151A1
· Tanaka et al.
· 2016
[cited by applicant]
US 20160279108A1
· Forrest et al.
· 2016
[cited by applicant]
US 20160354377A1
· Dar et al.
· 2016
[cited by applicant]
US 20170246305A1
· Shokat et al.
· 2017
[cited by applicant]
US 20190284146A1
· Yan et al.
· 2019
[cited by applicant]
US 20190336609A1
· Pitzen et al.
· 2019
[cited by applicant]
US 20210094975A1
· Aggen et al.
· 2021
[cited by applicant]
US 20210338824A1
· Pitzen et al.
· 2021
[cited by applicant]
US 20220340596A1
· Semko et al.
· 2022
[cited by applicant]
US 20230055672A1
· Pitzen et al.
· 2023
[cited by applicant]
US 20230093861A1
· Aggen et al.
· 2023
[cited by applicant]
US 20240100056A1
· Bitman et al.
· 2024
[cited by applicant]
US 20240166667A1
· Semko et al.
· 2024
[cited by applicant]
US 20240174615A1
· Ballmer et al.
· 2024
[cited by applicant]
CN 1132512A
· 1996
[cited by applicant]
CN 106188093A
· 2016
[cited by applicant]
EP 0088593A2
· 1983
[cited by applicant]
EP 0467606A1
· 1992
[cited by applicant]
EP 1916006A1
· 2008
[cited by applicant]
ES 2258763T3
· 2006
[cited by applicant]
GB 1459571A
· 1976
[cited by applicant]
JP H0249775A
· 1990
[cited by applicant]
JP H04112877A
· 1992
[cited by applicant]
JP H04230389A
· 1992
[cited by applicant]
JP H06211870A
· 1994
[cited by applicant]
JP H08503210A
· 1996
[cited by applicant]
JP H09505299A
· 1997
[cited by applicant]
JP 2004161716A
· 2004
[cited by applicant]
JP 2008273976A
· 2008
[cited by applicant]
JP 2009513222A
· 2009
[cited by applicant]
JP 2012528165A
· 2012
[cited by applicant]
JP 2016500112A
· 2016
[cited by applicant]
JP 2017500299A
· 2017
[cited by applicant]
JP 2017531624A
· 2017
[cited by applicant]
RU 2152946C1
· 2000
[cited by applicant]
RU 2322981C2
· 2008
[cited by applicant]
RU 2487711C2
· 2013
[cited by applicant]
WO WO9205179A1
· 1992
[cited by applicant]
WO WO9311130A1
· 1993
[cited by applicant]
WO WO9402136A1
· 1994
[cited by applicant]
WO WO9402485A1
· 1994
[cited by applicant]
WO WO1994004540A1
· 1994
[cited by applicant]
WO WO9409010A1
· 1994
[cited by applicant]
WO WO9411380A1
· 1994
[cited by applicant]
WO WO9425072A1
· 1994
[cited by applicant]
WO WO9504738A1
· 1995
[cited by applicant]
WO WO9514023A1
· 1995
[cited by applicant]
WO WO9516691A1
· 1995
[cited by applicant]
WO WO9641807A1
· 1996
[cited by applicant]
WO WO9936553A2
· 1999
[cited by applicant]
WO WO0114387A1
· 2001
[cited by applicant]
WO WO2004024719A1
· 2004
[cited by applicant]
WO WO2004101583A1
· 2004
[cited by applicant]
WO WO2005007085A2
· 2005
[cited by applicant]
WO WO2005105760A1
· 2005
[cited by applicant]
WO WO2006009518A1
· 2006
[cited by applicant]
WO WO2006068760A2
· 2006
[cited by applicant]
WO WO2006069038A1
· 2006
[cited by applicant]
WO WO2006116727A2
· 2006
[cited by applicant]
WO WO2007057457A2
· 2007
[cited by applicant]
WO WO2007061737A2
· 2007
[cited by applicant]
WO WO2007068462A2
· 2007
[cited by applicant]
WO WO2007114926A2
· 2007
[cited by applicant]
WO WO2007121453A2
· 2007
[cited by applicant]
WO WO2008046641A2
· 2008
[cited by applicant]
WO WO2008047821A1
· 2008
[cited by applicant]
WO WO2008065887A1
· 2008
[cited by applicant]
WO WO2008115974A2
· 2008
[cited by applicant]
WO WO2008127226A2
· 2008
[cited by applicant]
WO WO2009046436A1
· 2009
[cited by applicant]
WO WO2009088986A1
· 2009
[cited by applicant]
WO WO2009088990A1
· 2009
[cited by applicant]
WO WO2009089262A1
· 2009
[cited by applicant]
WO WO2009122176A2
· 2009
[cited by applicant]
WO WO2009131631A1
· 2009
[cited by applicant]
WO WO2010006072A2
· 2010
[cited by applicant]
WO WO2010006086A2
· 2010
[cited by applicant]
WO WO2010025406A1
· 2010
[cited by applicant]
WO WO2010036380A1
· 2010
[cited by applicant]
WO WO2010044885A2
· 2010
[cited by applicant]
WO WO2010051042A1
· 2010
[cited by applicant]
WO WO2010051043A1
· 2010
[cited by applicant]
WO WO2010138487A1
· 2010
[cited by applicant]
WO WO2011022439A1
· 2011
[cited by applicant]
WO WO2011022440A2
· 2011
[cited by applicant]
WO WO2011047384A2
· 2011
[cited by applicant]
WO WO2012017449A1
· 2012
[cited by applicant]
WO WO2012066502A1
· 2012
[cited by applicant]
WO WO2012103959A1
· 2012
[cited by applicant]
WO WO2012103960A1
· 2012
[cited by applicant]
WO WO2012151562A1
· 2012
[cited by applicant]
WO WO2012154695A2
· 2012
[cited by applicant]
WO WO2013077921A2
· 2013
[cited by applicant]
WO WO2014082286A1
· 2014
[cited by applicant]
WO WO2015066371A1
· 2015
[cited by applicant]
WO WO2015095755A1
· 2015
[cited by applicant]
WO WO2015184983A1
· 2015
[cited by applicant]
WO WO2016040806A1
· 2016
[cited by applicant]
WO WO2016100116A1
· 2016
[cited by applicant]
WO WO2017044720A1
· 2017
[cited by applicant]
WO WO2017121444A1
· 2017
[cited by applicant]
WO WO2018204416A1
· 2018
[cited by applicant]
WO WO2019064182A1
· 2019
[cited by applicant]
WO WO2019212990A1
· 2019
[cited by applicant]
WO WO2019212991A1
· 2019
[cited by applicant]
WO WO2020160711A1
· 2020
[cited by applicant]
WO WO2021257736A1
· 2021
[cited by applicant]
WO WO2022216900A2
· 2022
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2023/067503, mailed Nov. 7, 2024, 9 pages.
[cited by applicant]
Al-Muhammed et al. “In-vivo studies on dexamethasone sodium phosphate liposomes”, Journal of Microencapsulation, Jan. 1, 1996, vol. 13, No. 3, pp. 293-306.
[cited by applicant]
Anonyous, “Scientific Discussion,” EMEA, 2015, pp. 1-49.
[cited by applicant]
Apsel et al., “Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases,” Nature Chemical Biology, Nov. 2008, e-published Oct. 12, 2008, vol. 4, No. 11, pp. 691-699.
[cited by applicant]
Author Unknown “Basics of Medical Prevention,” Training Manual for Students and Cadets of Cycles of Professional Development of State Professional Educations Institutions. Novosibirsk, 2016, UDC 614.2-084, BBC 51.1(2)2,…
[cited by applicant]
Awad, M.M. et al., “Acquired Resistance to KRASG12C Inhibition in Cancer,” The New England Journal of Medicine, Jun. 24, 2021, vol. 384, pp. 2382-2393.
[cited by applicant]
Ayral-Kaloustian, S. et al., “Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conj…
[cited by applicant]
Banerjee, S.S. et al., “Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications,” J Drug Deliv, May 7, 2012, vol. 2012, p. 103973, 17 pages.
[cited by applicant]
Burnett L G., “Discovery of RMC-5552: A selective bi-steric inhibitor of mTORC1 that suppresses 4EBP1 phosphorylation, for the treatment of mTORC1-activated tumors including RAS pathway escape”, In: Proceedings of the A…
[cited by applicant]
Campanero, M. et al., “Therapeutic drug monitoring for sirolimus in whole blood of organ transplants by high-performance liquid chromatography with ultraviolet detection,” Journal of Chromotography, Mar. 26, 2004, vol. …
[cited by applicant]
CAS Registry No. 53123-88-9, accessed Feb. 27, 2018, 2 pages.
[cited by applicant]
Choi, J. et al., “Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP,” Science, Jul. 1996, vol. 273, No. 5272, pp. 239-242.
[cited by applicant]
Chonn et al. “Recent advances in liposomal drug-delivery systems”, Current Opinion in Biotechnology, Jan. 1, 1995, vol. 6, No. 6, pp. 698-708.
[cited by applicant]
Chou, T-C., “Drug combination studies and their synergy quantification using the Chou-Talalay method,” Cancer Research, Jan. 15, 2010, vol. 70, No. 2, pp. 440-446.
[cited by applicant]
Christensen, J., “The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancer,” Presentation at AACR-NCI-EORTC International Conference, Oct. 26-30, 2019, 30 pages, audio an…
[cited by applicant]
ClinicalTrials.gov, “Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies,” NCT No. NCT05054725, updated Apr. 3, 2023, 9 pages.
[cited by applicant]
ClinicalTrials.gov, “Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors,” NCT No. NCT05462717, updated Sep. 6, 2023, 7 pages.
[cited by applicant]
ClinicalTrials.gov, “Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors,” NCT No. NCT03634982, updated Sep. 1, 2022, 8 pages.
[cited by applicant]
ClinicalTrials.gov, “Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors,” NCT No. NCT04774952, updated Mar. 7, 2023, 8 pages.
[cited by applicant]
ClinicalTrials.gov, “Evaluation of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Specific Mutations in Kras,” Nct No. NCT05379985, updated Dec. 27, 2022, 7 pages.
[cited by applicant]
ClinicalTrials.gov, “History of Changes for Study: NCT04774952; Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors,” NCT No. NCT04774952, earliest publication date of Feb. 25, 2023, 4 pages.
[cited by applicant]
ClinicalTrials.gov, “Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101),” NCT No. NCT04185883, updated Sep. 14, 2023, 14 pages.
[cited by applicant]
Database Registry [Online], CAS Registry No. 1237826-20-8 (Aug. 23, 2010), 1 page.
[cited by applicant]
Database Registry [Online], CAS Registry No. 153984-91-9 (Mar. 30, 1994), 1 page.
[cited by applicant]
Dhaon, M. et al., “Synthesis, isolation, and characterization of ABT-578 equilibrium isomers,” Tetrahedron Letters, Dec. 22, 2006, vol. 48, pp. 1059-1062.
[cited by applicant]
Dorwald, F.Z., “Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design”, Weinheim: Wiley-VCH Verlag Gmbh & Co. KGaA, Mar. 6, 2006, Preface, 4 printed pages.
[cited by applicant]
Dowling, R.J. et al., “mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs,” Science, May 28, 2010, vol. 328, No. 5982, pp. 1172-1176.
[cited by applicant]
Drachman, J.G. et al., “Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer,” Hematology Am Soc Hematol Educ Program, Dec. 6, 2013, vol. 2013, No. 1, pp. 306-310.
[cited by applicant]
European Search Report in EP Application No. 23164819.7, by Pitzer et al., mailed Sep. 28, 2023, 18 pages.
[cited by applicant]
Extended European Search Report in EP Application No. 23164819.7, by Pitzer et al., mailed Jan. 25, 2024, 20 pages.
[cited by applicant]
Eyles et al., “Oral delivery and fate of poly(lactic acid) microsphere-encapsulated interferon in rats,” J Pharm Pharmacol., Jul. 1997, vol. 49, No. 7, pp. 669-674.
[cited by applicant]
Feldman M.E., et al., “Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2,” PLoS Biology, Feb. 2009, vol. 7, No. 2, pp. 0371-0383.
[cited by applicant]
Feldman et al., “New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor kinase domain inhibitors (TORKinibs),” Posphoinositide 3-kinase in Health and Disease, Jun. 2010, v…
[cited by applicant]
Flygare. J.A. et al. “Antibody-drug conjugates for the treatment of cancer,” Chem Biol Drug Des, Jan. 2013, vol. 81, No. 1, pp. 113-121.
[cited by applicant]
Galat, “Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands,” Cell Mol Life Sci., Sep. 7, 2013, vol. 70, No. 18, pp. 3243-3275.
[cited by applicant]
Gao et al., “Controlled release of a contraceptive steroids from biodegradable and injectable gel formulations: in vitro evaluation,” Pharm Res., 1995, vol. 12, No. 6, pp. 857-863.
[cited by applicant]
Guo et al., “High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response,” Nature Medicine, Oct. 19, 2015, vol. 21, No. 11, pp. 1318-1325.
[cited by applicant]
Hackam et al. “Translation of research evidence from animals to humans,” JAMA, Oct. 11, 2006, vol. 296, No. 14, pp. 1727-1732.
[cited by applicant]
Hara, K. et al., “Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action,” Cell, Jul. 26, 2002, vol. 110, No. 2, pp. 177-189.
[cited by applicant]
Hsieh, A.C. et al., “The translational landscape of mTOR signalling steers cancer initiation and metastasis,” Nature, Feb. 22, 2012, vol. 485, No. 7396, pp. 55-61.
[cited by applicant]
Hsieh, A.C. et al., “Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-el F4E,” Cancer Cell, Mar. 16, 2010, vol. 17, No. 3, pp. 249-261.
[cited by applicant]
Hughes et al., “The isolation, synthesis and characterization of an isomeric form of rapamycin,” Tetrahedron Letters, Aug. 11, 1992, vol. 33, Issue 33, pp. 4739-4742.
[cited by applicant]
Il'Ichev et al., “Degradation of rapamycin and its ring-opened isomer: role of base catalysis,” Arkivoc, May 6, 2007, vol. 12, pp. 110-131.
[cited by applicant]
Infante, J. R. et al., “Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-h…
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2023/067503, by Bitman et al., mailed Jul. 19, 2023, 15 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2022/023778, by Ballmer et al., mailed Nov. 25, 2022, 18 pages.
[cited by applicant]
International Search Report for PCT Application No. PCT/US2015/049693, by Shokat et al., mailed Dec. 14, 2015, 3 pages.
[cited by applicant]
International Search Report for PCT Application No. PCT/US2018/030531, by Aggen et al., mailed Aug. 28, 2018, 16 pages.
[cited by applicant]
International Search Report for PCT Application No. PCT/US2019/029737, by Pitzen et al., mailed Sep. 23, 2019, 12 pages.
[cited by applicant]
International Search Report for PCT Application No. PCT/US2019/029738, by Semko et al., mailed Jun. 26, 2019, 4 pages.
[cited by applicant]
Jacinto et al., “Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive,” Nat Cell Biol, Nov. 1, 2004, vol. 46, No. 11, pp. 1122-1128.
[cited by applicant]
Jordan, “Tamoxifen: A most Unlikely Pioneering Medicine, ” Nature Reviews: Drug Discovery, Mar. 2003, vol. 2, No. 3, pp. 205-213.
[cited by applicant]
Kallen et al., “X-ray Crystal Structure of 28-O-Methylrapamycin complexed with FKBP12: Is the Cyclohexyl Moiety Part of the Effector Domain of Rapamycin,” J. Am. Chem. Soc., Jun. 26, 1996, vol. 118, No. 25, pp. 5857-586…
[cited by applicant]
Katritzky et al., “QSAR modeling, synthesis and bioassay of diverse leukemia RPMI-8226 cell line active agents,” Eur J Med Chem., Nov. 2010, vol. 45, No. 11, pp. 5183-5199.
[cited by applicant]
Katritzky et al., “Tautomerism in drug discovery,” Journal of computer-aided molecular design, Jun. 2010, vol. 24, Nos. 6-7, pp. 475-484.
[cited by applicant]
Kearns et al., “Developmental pharmacology—drug disposition, action, and therapy in infants and children,” New England Journal of Medicine, Sep. 18, 2003, vol. 349, No. 12, p. 1157-1167.
[cited by applicant]
Kim, D.H. et al., “mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery,” Cell, Jul. 26, 2002, vol. 110, No. 2, pp. 163-175.
[cited by applicant]
Kümmerer, K., et al., “Pharmaceuticals in the Environment,” Annual Review of Environment and Resources, Aug. 18, 2010, vol. 35, pp. 57-75.
[cited by applicant]
Kolb et al. “Click Chemistry: Diverse Chemical Function from a Few Good Reactions.” Angewandte Chemie International Edition, Jun. 1, 2001, vol. 40, No. 11, pp. 2004-2021.
[cited by applicant]
Lamming, D.W. et al., “Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity,” Science, Mar. 309, 2012, vol. 335, No. 6076, pp. 1638-1643.
[cited by applicant]
Lee, BJ et al., “Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth,” Nat Chem Biol., Oct. 2021, vol. 17, No. 10, pp. 1065-1074.
[cited by applicant]
Liu et al., “Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for…
[cited by applicant]
Luengo et al., “Manipulation of the Rapamycin Effector Domain. Selective Nucleophilic Substitution of the C7 Methoxy Group,” Org. Chem., Nov. 1994, vol. 59, No. 22, pp. 6512-6513.
[cited by applicant]
Luengo, J. et al., “Studies on Selective Reductions of Rapamycin,” Tetrahedron Letters, Aug. 29, 1994, vol. 35, No. 35, pp. 6469-6472.
[cited by applicant]
Mashkovsky, M. D., “Medicaments (Doctor's Manual)”, 14th Edition, 2001, vol. 1, Moscow, pp. 11; 6 pages with English translation.
[cited by applicant]
Masuda, et al., “Synthesis of Alkoxy-, (Alkylthio)-, Phenoxy-, and (Phenylthio)pyrazines and their Olfactive Properties,” J. Agric. Food Chem., Mar. 1986, vol. 34, No. 2, pp. 377-381.
[cited by applicant]
McCormick, M.A. et al., “TOR and ageing: a complex pathway for a complex process,” McCormick MA, Tsai SY, Kennedy BK. Tor and ageing: a complex pathway for a complex process. Philosophical Transactions of the Royal Soci…
[cited by applicant]
Moni et al., “Synthesis of rapamycin glycoconjugates via a CuAAC-based approach,” Tetrahedron Letters, Dec. 18, 2013 vol. 54, No. 51, pp. 6999-7003.
[cited by applicant]
Naing, A. et al. “Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma,” Br J Cancer, Sep. 25, 2012, vol. 107, No. 7, pp. 1093-1099.
[cited by applicant]
Neasta, J. et al., “mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse,” J Neurochem, Jul. 2014, vol. 130, No. 2, pp. 172-184.
[cited by applicant]
Nelson et al., “Manipulation of the C(22)-C(27) Region of Rapamycin: Stability Issues and Biological Implications,” Bioorganic & Medicinal Chemistry Letters, Jan. 18, 1999, vol. 9, No. 2, pp. 295-300.
[cited by applicant]
Nelson, F.C. et al., “A Novel Ring Contraction of Rapamycin,” Tetrahedron Letters, Oct. 10, 1994, vol. 35, No. 41, pp. 7557-7560.
[cited by applicant]
Nowak et al., “Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase,” J Med Chem., Nov. 2009, vol. 52, No. 22, pp. 7081-7089.
[cited by applicant]
O'Donnell, A et al., “Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors,” J Clin Onco, Apr. 1, 2008, vol. 26, No. 10,…
[cited by applicant]
Ohbayashi, Y., et al., “Topical steroid injection for refractory oral chronic graft-versus-host disease” Rinsho Ketsueki, Nov. 1, 2007, vol. 48, No. 11, pp. 1508-1510.
[cited by applicant]
O'Reilly, K.E. et al., “mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt,” Cancer Res, Feb. 1, 2006, vol. 66, No. 3, p. 1500-1508.
[cited by applicant]
Ostro MJ, et al. “Use of liposomes as injectable-drug delivery systems”, American Journal of Hospital Pharmacy, Aug. 1, 1989, vol. 46, No. 8, pp. 1576-1587.
[cited by applicant]
Pokrovsky, V. I., “Small Medical Encyclopedia,” Medicine, 1996, V5, pp. 90-96; 12 pages with English translation of relevant portion.
[cited by applicant]
Prior et al., “The Frequency f Ras Mutations in Cancer,” Cancer Research, Jul. 2020, vol. 80, No. 14, pp. 2969-2974.
[cited by applicant]
Rao, K.P., “Recent developments of collagen-based materials for medical applications and drug delivery systems,” J Biomater Sci Polym Ed, Jan. 1, 1996, vol. 7, No. 7, pp. 623-645.
[cited by applicant]
Revolution Medicines, Inc., “On Target to Outsmart Cancer™,” Corporate Presentation, Jan. 10, 2023, 32 pages.
[cited by applicant]
Revolution Medicines, Inc., “On Target to Outsmart Cancer™,” Corporate Presentation, Jan. 11, 2022, 33 pages.
[cited by applicant]
Revolution Medicines, Inc., “Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor,” Press Release dated Dec. 19, 2022, 2 pages.
[cited by applicant]
Revolution Medicines, Inc., “Targeting KRASG12C(ON) and Potential Application to Overcoming Drug Resistance in RAS-Addicted Tumors,” RAS-Targeted Drug Development, Sep. 22, 2021, 16 pages.
[cited by applicant]
Revolution Medicines, Inc., “The Bi-steric mTORC1-Selective Inhibitor RMC-5552 in Tumors with Activation of mTOR Signaling: Preclinical Activity in Combination with RAS(ON) Inhibitors in RAS-Addicted Tumors, and Initial…
[cited by applicant]
Rhodes, N. et al., “Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity,” Cancer Res, Apr. 1, 2008, vol. 68, No. 7, pp. 2366-2374.
[cited by applicant]
Ricciutelli, M. et al., “Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC,” Journal of Pharmaceutical and Biomedical Analysis, Mar. 20, 2006, vol. 41, pp. 1070-1074.
[cited by applicant]
Rodrik-Outmezguine, V.S. et al., “mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling,” Cancer Discov, Aug. 2011, vol. 1, No. 3, pp. 248-259.
[cited by applicant]
Rodrik-Outmezguine, V.S., et al., “Overcoming mTOR Resistance Mutations with a New-Generation mTOR Inhibitor,” Nature, Jun. 9, 2016, vol. 534, No. 7606, 28 pages.
[cited by applicant]
Ruggero, D. et al., “The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis,” Nat Med, Apr. 18, 2004, vol. 10, No. 5, pp. 484-486.
[cited by applicant]
Sanchez-Martinez, Conception, “Cyclin dependent kinase (CDK) inhibitors as anticancer drugs”, Bioorganic & Medicinal Chemistry Letters, Pergamon, Jun. 6, 2015, vol. 25, No. 17, pp. 3420-3435.
[cited by applicant]
Sarbassov et al., “Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB,” Mol Cell, Apr. 21, 2006, vol. 22, No. 2, pp. 159-168.
[cited by applicant]
Sarbassov et al., “Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton,” Curr Biol, Jul. 27, 2004, vol. 14, No. 14, pp. 1296-1302.
[cited by applicant]
Shu et al., “Synthesis of I125 labeled photoaffinity rapamycin analogs,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 38, No. 3, Mar. 1996, vol. 38, No. 3, pp. 227-237.
[cited by applicant]
Sobhani, H. et al., “A Reversed Phase High Performance Liquid Chromatographic Method for Determination of Rapamycin,” Iranian Journal of Pharmaceutical Research, Feb. 2013, vol. 12 (Supp), pp. 77-81.
[cited by applicant]
Strom et al., “Structural identification of SAR-943 metabolites generated by human liver microsomes in vitro using mass spectrometry in combination with analysis of fragmentation patterns,” J. Mass. Spectrom., Jul. 2011…
[cited by applicant]
Su, K. Y. et al., “Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer,” J Clin Oncol, Feb. 1…
[cited by applicant]
Tallarida, R.J., “Quantitative methods for assessing drug synergism,” Genes and cancer, Nov. 2011, vol. 2, No. 11, pp. 1003-1008.
[cited by applicant]
Tanaka, N. et al., “Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation,” AACR Cancer Discovery, Aug. 2021, v…
[cited by applicant]
Thoreen C.C., et al., “An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1,” Journal of Biological Chemistry, Mar. 2009, vol. 284, No. 12, pp. 8023-8032.
[cited by applicant]
Umeda, N. et al., “A photocleavable rapamycin conjugate for spatiotemporal control of small GTPase activity,” J Am Chem Soc, Dec. 13, 2010, vol. 133, No. 1, pp. 12-14.
[cited by applicant]
Vengerovskiy, A. I., “Pharmacological incompatibility,” Bulletin of Siberian Medicine, Sep. 30, 2003, vol. 2, No. 3, pp. 49-56; 16 pages (English translation of Russian Office Action for Russian Application No. 20131073…
[cited by applicant]
Viale, PH., “The American Cancer Society's Facts & Figures: 2020 Edition,” Journal of the Advanced Practitioner in Oncology, Mar. 2020, vol. 11, No. 2, pp. 135-136.
[cited by applicant]
Wagner, R. et al., “Rapamycin analogs with reduced systemic exposure,” Bioorganic Medicinal Chemistry Letters, Sep. 26, 2005, vol. 15, pp. 5340-5343.
[cited by applicant]
Wood, E.R. et al., “A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells,” Cancer Res,…
[cited by applicant]
Written Opinion for Intl. App. No. PCT/US2015/049693, by Shokat et al., mailed on Mar. 17, 2016, 7 pages.
[cited by applicant]
Wyeth Laboratories, Rapamune® (sirolimus) Oral Solution Tablets, Jan. 2007, 37 pages, retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021083s030,021110s038lbl.pdf.
[cited by applicant]
Xie et al., “Design, Synthesis and Biological Evaluation of Novel Rapamycin Benzothiazole Hybrids as mTOR Targeted Anti-cancer Agents,” Chem Pharm Bull, Apr. 1, 2016, vol. 64, No. 4, pp. 346-355.
[cited by applicant]
Xie et al., “Synthesis of Rapamycin Derivatives Containing the Triazole Moiety Used as Potential mTOR-Targeted Anticancer Agents,” Arch Pharm (Weinheim), Jun. 2016, vol. 349, No. 6, pp. 428-441.
[cited by applicant]
Xu et al., “The combination of RAD001 and NVP—BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo,” PLoS One, Jun. 14, 2011, vol. 6, No. 6, p. e20899, 8 pages.
[cited by applicant]
Yamanishi, et al., “Syntheses of trimethylpyrazines and their antibacterial properties,” Yakugaku Zasshi, Jan. 1967, vol. 87, No. 1, pp. 105-107.
[cited by applicant]
Yang, H. et al., “mTOR kinase structure, mechanism and regulation,” Nature, May 1, 2013, vol. 497, No. 7448, pp. 217-223.
[cited by applicant]
Yohannes, D. et al., “Degradation of Rapamycin Retrieval of Major Intact Subunits,” Tetraheron Letters, Jan. 1, 1992, vol. 33, No. 49, pp. 7469-7472.
[cited by applicant]
Zeng, H. et al., “mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function,” Nature, Jun. 30, 2013, vol. 7459, pp. 485-490.
[cited by applicant]